KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Accumulated Expenses: 2020-2024

Historic Accumulated Expenses for Royalty Pharma (RPRX) over the last 5 years, with Dec 2024 value amounting to $98.1 million.

  • Royalty Pharma's Accumulated Expenses fell 24.39% to $29.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.0 million, marking a year-over-year decrease of 24.39%. This contributed to the annual value of $98.1 million for FY2024, which is 89.74% up from last year.
  • As of FY2024, Royalty Pharma's Accumulated Expenses stood at $98.1 million, which was up 89.74% from $51.7 million recorded in FY2023.
  • Royalty Pharma's Accumulated Expenses' 5-year high stood at $98.1 million during FY2024, with a 5-year trough of $42.1 million in FY2020.
  • Moreover, its 3-year median value for Accumulated Expenses was $54.2 million (2022), whereas its average is $68.0 million.
  • As far as peak fluctuations go, Royalty Pharma's Accumulated Expenses dropped by 6.13% in 2022, and later spiked by 89.74% in 2024.
  • Yearly analysis of 5 years shows Royalty Pharma's Accumulated Expenses stood at $42.1 million in 2020, then spiked by 36.90% to $57.7 million in 2021, then fell by 6.13% to $54.2 million in 2022, then fell by 4.58% to $51.7 million in 2023, then soared by 89.74% to $98.1 million in 2024.